Public source

Reviewed 2 Oct 2026

Completeness Fair (36%)

Waiv MSIntuit® CRC

Owkin Inc. (Waiv)

MSIntuit CRC is an AI digital pathology diagnostic solution that pre-screens for a biomarker in colorectal cancer tumors known as microsatellite instability (MSI) – a defect in a cell’s ability to correct mistakes that occur when DNA is copied. This diagnostic rules out microsatellite stable (MSS) phenotypes, allowing pathologists to concentrate their resources on confirming those patients who exhibit MSI.

Supported by 1 paper

Key features

Biomarker prediction

General Information

Product name

Waiv MSIntuit® CRC

Modality

Histopathology

Main task

Biomarker identification

Subspeciality

Gastrointestinal pathology

Organ/Specimen source

Not specified

Disease targeted

Colorectal cancer

Specimen type

Not specified

Staining

H&E

Stain subtype

Not specified

Regulatory Information

CE-IVD Certification

Pathway:

In Vitro Diagnostic Regulation (IVDR)

Class:

Class C

Not verified by Health AI Register

Scanner Brands Certified for Use (CE-IVD)

Not specified

Scanner Models Certified for Use (CE-IVD)

Not specified

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

Not specified

Input format

Not specified

Output

Not specified

Output format

Not specified

Integration

Not specified

Deployment

Not specified

Trigger for analysis

Not specified

Processing time

Not specified

Population

Not specified

Viewer systems

Not specified

Market Presence

On market since

Not specified

AI Platforms

Roche Navify

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Not specified

Source: Public | First published: Aug 1, 2025 | Last updated: Oct 2, 2026